EUpertstrain 4 Study of Bordetella Pertussis Isolates

University of Turku

Status

Completed

Conditions

Bordetella Pertussis, Whooping Cough

Treatments

Other: Strain isolation from the nasopharynx

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT03197597

EUpert IV

Details and patient eligibility

About

This study focus on the genetic changes of B. pertussis clinical isolates. For this panels of B. pertussis isolates has been collected during four periods in different European countries.

Full description

B. pertussis is considered as a monomorphic pathogen. However, genetic changes have been observed in several antigens (pertussis toxin, pertactin, filamentous haemagglutinin and fimbriae) included in the current acellular pertussis vaccines between vaccine strains and circulating isolates.

To study genetic changes in the B. pertussis populations in Europe, four distinct panels have been collected: EUpert I in 1999-2001 including 102 isolates, EUpert II in 2004-2005 including 154 isolates, EUpert III in 2007-2009 including 140 isolates and EUpert IV in 2012-2015 including 265 isolates. Selection criteria have remained unchanged for all four collections, which enables the opportunity to study changes in B. pertussis populations during the last 15 years.

Enrollment

265 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

B. pertussis clinical isolates should be collected from subjects from different regions and be epidemiologically unrelated.
An equal number of isolates from vaccinated and unvaccinated subjects should be collected. Optimally, the isolates are preferred to be selected from individuals less than 5 years of age.
For countries with large numbers of isolates in their collections, isolates should be randomly selected according to criteria above.

Exclusion criteria